At the Ophthalmology Futures Forum, EyeYon Medical shared an important milestone in the journey of EndoArt® — two years since the start of its limited
Today, we’re thrilled to celebrate a major milestone at EyeYon Medical: the 400th commercial implantation of EndoArt® since its launch in September 2023! This achievement
What began nearly 14 years ago as a bold idea—to rethink the way we treat corneal endothelial disease—has become a reality that’s now changing lives.
As the American Society of Cataract and Refractive Surgery (ASCRS) meeting wraps up, sharing this beautiful moment captured at the event: A proud snapshot 📸featuring:
🚀 Just wrapped up an incredible session at AECOS (American-European Congress of Ophthalmic Surgery) in London! and the response was electric ⚡ 🧠 From innovation
Up to 6-year follow-up shows significant corneal edema reduction, stable outcomes, and no serious implant-related complications after first human EndoArt® implantation
First reported case of atypical endophthalmitis following EndoArt artificial endothelial implantation. A conservative surgical approach preserved corneal clarity and achieved infection control.
EyeYon Medical was proud to participate in the 43rd Congress of the European Society of Cataract and Refractive Surgeons (ESCRS), held in Copenhagen. Our team
EyeYon Medical was featured in The Ophthalmologist with a comprehensive article exploring seven clinical patient profiles that help guide the use of EndoArt® in the
The first day of the 43rd ESCRS Congress in Copenhagen marked an exciting start for EyeYon Medical!Our team began an inspiring series of sessions, discussions,
A look inside our booth at the 43rd ESCRS Congress in Copenhagen — where innovation meets collaboration!Our team was thrilled to showcase EndoArt® and connect
What an incredible few days at the 43rd Congress of the European Society of Cataract and Refractive Surgeons (ESCRS) in Copenhagen! EyeYon Medical was proud
The study evaluates the long-term outcomes of the EndoArt artificial endothelial implant in patients with chronic corneal edema. Over two years, the device significantly improved
This 4.5-year follow-up study of the EndoArt corneal endothelial prosthesis showed 90% long-term adherence, significant reduction in central corneal thickness, and visual improvement in 60%
Detailed review and clinical insights into EndoArt use for chronic corneal oedema cases.
Retrospective findings on EndoArt effectiveness in GDD patients with high transplant failure risk.
Case demonstrating novel technique ensuring safe EndoArt placement in high-risk scenarios.
Short-term improvement in corneal clarity and reduced edema after EndoArt implantation.
Alternative implantation method reducing complications in severe endothelial dysfunction cases.
Promising outcomes in high-risk patients with complex ocular conditions using EndoArt.
Demonstrated safety and efficacy in treating chronic corneal edema across multi-center trials.
Alternative for patients experiencing multiple transplant failures and high rejection rates.
Improved outcomes post-EndoArt for repeat keratoplasty failure with limited complications.
Innovative method aiding EndoArt use in complex ocular conditions over 1-year follow-up.
Early human trials of the EndoArt artificial corneal implant show it to be safe and effective in reducing corneal thickness without adverse events over 12
Reports the first artificial corneal endothelial transplantation in China, demonstrating significant improvement in severe corneal edema.
Early trials of the EndoArt artificial endothelial implant, including Heidelberg’s 2-year follow-up, show promising safety and efficacy, making it a viable option for treating endothelial
Dutch eye surgeon Dr. Ruth Lapid-Gortzak collaborated with EyeYon Medical to test a synthetic corneal endothelial implant as a solution to donor shortages. A first
Implantation of an artificial endothelial layer (EndoArt®, EyeYon Medical) is a promising treatment for select eyes with chronic corneal oedema from corneal endothelial dysfunction, according
A novel artificial endothelial implant may provide a safe, efficient, and cost-effective treatment modality for chronic corneal oedema and dispense the need for donor tissue
Reviews current and emerging therapies for corneal endothelial regeneration, addressing the global tissue shortage and innovative treatments such as EndoArt. dysfunction.
EndoArt demonstrates potential as a synthetic solution for chronic corneal edema management.
